Trial reportTrials2010
The Viborg Vascular (VIVA) screening trial of 65-74 year old men in the central region of Denmark: study protocol.
Trial report in Trials, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00662480 (Randomized Preventive Vascular Screening Trial of 65-74 Year Old Men in the Central Region of Denmark), which is not on this map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Preventive Vascular Screening Trial of 65-74 Year Old Men in the Central Region of Denmark
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The association between diabetes and abdominal aortic aneurysms in men: results of two Danish screening studies, a systematic review, and a meta-analysis of population-based screening studies.BMC cardiovascular disorders · 2023Pooled it
- Critical appraisal of international guidelines for the screening and treatment of asymptomatic peripheral artery disease: a systematic review.BMC cardiovascular disorders · 2019Pooled it
- Pooled it
- Screening for peripheral arterial disease.The Cochrane database of systematic reviews · 2014Pooled it
- Asthma Associates With Human Abdominal Aortic Aneurysm and Rupture.Arteriosclerosis, thrombosis, and vascular biology · 2016Trial
- The Danish Cardiovascular Screening Trial (DANCAVAS): study protocol for a randomized controlled trial.Trials · 2015Trial
- Plasma cathepsin S and cystatin C levels and risk of abdominal aortic aneurysm: a randomized population-based study.PloS one · 2012 · on this mapTrial
- Therapeutic Strategies for Abdominal Aortic Aneurysm: A Comprehensive Systematic Review.Journal of cardiovascular development and disease · 2025Review
- Immunoglobulin A/PIGR axis as potential mediators of human abdominal aortic aneurysms revealed by topologically resolved proteomics.Journal of translational medicine · 2025Article
- Article
- Basement membrane collagen IV deficiency promotes abdominal aortic aneurysm formation.Scientific reports · 2021Article
- IgG Anti-High Density Lipoprotein Antibodies Are Elevated in Abdominal Aortic Aneurysm and Associated with Lipid Profile and Clinical Features.Journal of clinical medicine · 2019Article
- Do Non-participants at Screening have a Different Threshold for an Acceptable Benefit-Harm Ratio than Participants? Results of a Discrete Choice Experiment.The patient · 2019Article
- Plasma Cystatin B Association With Abdominal Aortic Aneurysms and Need for Later Surgical Repair: A Sub-study of the VIVA Trial.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery · 2018Article
- Arachidonic Acid, but Not Omega-3 Index, Relates to the Prevalence and Progression of Abdominal Aortic Aneurysm in a Population-Based Study of Danish Men.Journal of the American Heart Association · 2018Observational
- Plasma cytokine levels and risks of abdominal aortic aneurysms: A population-based prospective cohort study.Annals of medicine · 2015Article
- Scientific second-order 'nudging' or lobbying by interest groups: the battle over abdominal aortic aneurysm screening programmes.Medicine, health care, and philosophy · 2014Article
- IgE actions on CD4+ T cells, mast cells, and macrophages participate in the pathogenesis of experimental abdominal aortic aneurysms.EMBO molecular medicine · 2014Article
- Novices may be trained to screen for abdominal aortic aneurysms using ultrasound.Cardiovascular ultrasound · 2013Article
- Plasma levels of cathepsins L, K, and V and risks of abdominal aortic aneurysms: a randomized population-based study.Atherosclerosis · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundScreening for abdominal aortic aneurysm (AAA) of men aged 65-74 years reduces the AAA-related mortality and is generally considered cost effective. Despite of this only a few national health care services have implemented permanent programs. Around 10% of men in this group have peripheral arterial disease (PAD) defined by an ankle brachial systolic blood pressure index (ABI) below 0.9 resulting in an increased mortality-rate of 25-30%. In addition well-documented health benefits may be achieved through primary prophylaxis by initiating systematic cholesterol-lowering, smoking cessation, low-dose acetylsalicylic acid (aspirins), exercise, a healthy diet and blood-pressure control altogether reducing the increased risks for cardiovascular disease by at least 20-25%. The benefits of combining screening for AAA and PAD seem evident; yet they remain to be established. The objective of this study is to assess the efficacy and the cost-effectiveness of a combined screening program for AAA, PAD and hypertension.
methodsThe Viborg Vascular (VIVA) screening trial is a randomized, clinically controlled study designed to evaluate the benefits of vascular screening and modern vascular prophylaxis in a population of 50,000 men aged 65-74 years. Enrolment started October 2008 and is expected to stop in October 2010. The primary outcome is all-cause mortality. The secondary outcomes are cardiovascular mortality, AAA-related mortality, hospital services related to cardiovascular conditions, prevalence of AAA, PAD and potentially undiagnosed hypertension, health-related quality of life and cost effectiveness. Data analysis by intention to treat.
resultsMajor follow-up will be performed at 3, 5 and 10 years and final study result after 15 years.
trial registrationClinicalTrials.gov NCT00662480.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.